Focus:
News
-
20 September 2019
FDA grants RMAT designation to SanBio’s cell therapy
The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to SanBio Group’s cell therapy, SB623, to treat chronic neurological motor deficits secondary to traumatic...
-
20 September 2019
NICE recommends Takeda’s Takhzyro in hereditary angioedema
The UK’s National Institute for Health and Clinical Excellence (NICE) has recommended the use of subcutaneous injection of Takeda’s Takhzyro (lanadelumab) to prevent recurrent attacks of hereditary angioedema (HAE).
-
20 September 2019
Researchers use three-drug combination to treat lung cancer
A study by the Francis Crick Institute and The Institute of Cancer Research, London has tested the combination of a G12C KRAS inhibitor with mTOR and IGF1R inhibitors for the...
-
19 September 2019
Novartis presents additional Zolgensma data in children with SMA
Novartis subsidiary AveXis has announced interim data for Zolgensma (onasemnogene abeparvovec-xioi) in children with spinal muscular atrophy (SMA) type 1, the most severe form of the neurodegenerative condition, for trials...
-
19 September 2019
Versantis raises funds to advance liver disease drugs
Swiss biotech firm Versantis has completed a series B funding round to support the clinical development of new therapies to treat liver diseases.
-
19 September 2019
AstraZeneca revises Linzess deal with Ironwood Pharmaceuticals
AstraZeneca has revised its agreement with Ironwood Pharmaceuticals for irritable bowel syndrome with constipation (IBS-C) drug Linzess (linaclotide).
-
19 September 2019
Roche receives FDA breakthrough status for lupus nephritis drug
Roche has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for its Gazyva (obinutuzumab) to treat lupus nephritis in adults.
-
18 September 2019
FDA approves Keytruda plus Lenvima for endometrial carcinoma
The US Food and Drug Administration (FDA) has approved Merck’s anti-programmed cell death protein 1 (PD-1) Keytruda and Eisai’s kinase inhibitor Lenvima for certain advanced endometrial carcinoma patients.
-
18 September 2019
US FDA partners Australia and Canada for cancer therapies review
The US Food and Drug Administration (FDA) has partnered with the Australian Therapeutic Goods Administration (TGA) and Health Canada to expedite the approval of oncology therapies.
-
18 September 2019
Study shows use of arthritis drug in blood cancer treatment
A study led by the University of Sheffield, UK, has demonstrated that a low-cost rheumatoid arthritis drug, methotrexate (MTX), can help to treat patients with blood cancer.